ChatGPT Parent Open AI Partners With Sanofi, Formation Bio To Boost AI-Driven Drug Development
ChatGPT Parent Open AI Partners With Sanofi, Formation Bio To Boost AI-Driven Drug Development
Tuesday, French drugmaker Sanofi SA (NASDAQ:SNY) announced its collaboration with OpenAI and Formation Bio to accelerate drug development projects.
周二，法国制药商赛诺菲公司（纳斯达克股票代码：SNY）宣布与OpenAI和Formation Bio合作，以加快药物开发项目。
Also Read: Drugmaker Sanofi's Strong Dupixent And Beyfortus Vaccine Sales Propel Q1 Earnings.
另请阅读： 制药商赛诺菲强劲的Dupixent和Beyfortus疫苗销售推动了第一季度的收益。
Sanofi said the partnership with OpenAI will allow it to access proprietary data to develop AI models for its biopharma models, while Formation Bio will provide additional engineering resources.
赛诺菲表示，与OpenAI的合作将使其能够访问专有数据，为其生物制药模型开发人工智能模型，而Formation Bio将提供额外的工程资源。
The three teams will combine data, software, and tuned models to develop custom, purpose-built solutions for the drug development lifecycle.
这三个团队将结合数据、软件和调整后的模型，为药物研发生命周期开发定制的专用解决方案。
OpenAI will contribute access to AI capabilities, including the ability to fine-tune models, deep AI expertise, and dedicated thought partnerships and resources.
OpenAI 将提供获得人工智能功能的机会，包括微调模型的能力、深厚的人工智能专业知识以及专门的思想伙伴关系和资源。
Formation Bio, an AI and tech-driven drug developer with its pipeline of drug assets, will provide engineering resources, experience operating at the intersection of pharma and AI, and its tech-driven development platform to design, develop, and deploy AI technologies across all aspects of the pharma lifecycle.
Formation Bio是一家拥有药物资产管道的人工智能和技术驱动的药物开发商，将提供工程资源、在制药和人工智能交汇处的运营经验以及技术驱动的开发平台，用于设计、开发和部署制药生命周期的各个方面的人工智能技术。
The potential benefits of AI for patients awaiting new treatments are immense, and Sanofi, Formation Bio, and OpenAI aim to set the standard for drug developers.
对于等待新疗法的患者来说，人工智能的潜在好处是巨大的，赛诺菲、Formation Bio和OpenAI的目标是为药物开发商设定标准。
Last month, Moderna Inc (NASDAQ:MRNA) and Microsoft Corp (NASDAQ:MSFT)-backed OpenAI announced their ongoing collaboration to co-innovate.
上个月，摩德纳公司（纳斯达克股票代码：MRNA）和微软公司（纳斯达克股票代码：MSFT）支持的OpenAI宣布正在进行合作以共同创新。
Moderna began a collaboration with OpenAI in early 2023 with the launch of Moderna's own instance of ChatGPT, called mChat. The company announced Wednesday that it has reached more than 80% internal adoption of mChat, which has accelerated the AI culture at Moderna.
Moderna 于 2023 年初开始与 OpenAI 合作，推出了 Moderna 自己的名为 mChat 的 ChatGPT 实例。该公司周三宣布，其内部对mChat的采用率已达到80％以上，这加速了Moderna的人工智能文化。
Price Action: SNY shares are down 0.62% at $48.12 during the premarket session at last check Tuesday.
价格走势：周二最后一次盘前交易中，纽约证券交易所股价下跌0.62％，至48.12美元。
Photo via Shutterstock
照片来自 Shutterstock